Carregant...
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have cle...
Guardat en:
| Publicat a: | Nephrol Dial Transplant |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993192/ https://ncbi.nlm.nih.gov/pubmed/32003833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz252 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|